Novartis gains 8% in 6 months following FDA commissioner appointment

Novartis, with a robust pipeline and lower regulatory risk, will benefit from a stable FDA leadership team. Investors will rotate into Novartis as a defensive play during the transition period.

Implied probability (Yes)

55%